Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

Diabetic Medicine

Volumn 21, Issue 5, 2004, Pages 415-422

  Bennett, S M A ^a,e   Agrawal, A ^b   Elasha, H ^c   Heise, M ^d   Jones, N P ^b   Walker, M ^a   Wilding, J P H ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Ambulatory blood pressure; Impaired glucose tolerance; Insulin sensitivity; Rosiglitazone

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; HUMAN; HYPERINSULINISM; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; THIAZOLIDINEDIONES;

EID: 2342617443     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01155.x     Document Type: Article

References (34)

1. The Decode Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 354: 617-621.
2. Harris MI. Impaired glucose tolerance in the US population. Diabetes Care 1992; 12: 464-474.
3. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46: 701-710.
4. Keen H, Jarret RJ, McCartney P. The ten-year follow-up of the Bedford Study (1962-72): glucose tolerance and diabetes. Diabetologia 1982; 22: 73-78.
5. Motala AA, Omar MAK, Gouws E. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM. Diabetes Care 1997; 20: 1101-1107.
6. Butterfield WJH. Summary results of the Bedford Diabetes Study. Proc R Soc Med 1964; 57: 196-200.
7. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1980; 1: 1373-1376.
8. Reaven GM, Lithel H, Landsberg L. Mechanisms of disease: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
9. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle amongst subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
10. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
11. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type D diabetes. Diabetes 1996; 45: 1661-1669.
12. Fürnsinn C, Waldhäusl W. Thiazolidenediones: metabolic actions in vitro. Diabetologia 2002; 45: 1211-1223.
13. Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
14. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203-1210.
15. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 1997; 46: 935-942.
16. Krebbs M, Krssak M, Nowotny P, Weghuber D, Gruber S, Mlynarik V et al. Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. J Clin Endocrinol Metab 2001; 86: 2153-2160.
17. Preininger K, Stingl H, Englisch R, Furnsinn C, Graf J, Waldhausl W et al. Acute troglitazone action in isolated perfused rat liver. Br J Pharmacol 1999; 126: 372-378.
18. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 128: 176-185.
19. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
20. Wolffenbuttel BHR, Gomist R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40-47.
21. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 2000; 283: 1695-1702.
22. WHO Study Group on Diabetes Mellitus. Diabetes Mellitus. Report of a WHO Study Group. Technical Report Series 727. Geneva: World Health Organization, 1985.
23. Miyazaki Y, Glass L, Triplitt C, Matsuda Y, Cusi K, Mahankali A et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44: 2210-2219.
24. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1189.
25. Speigelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
26. Antonucci T, Whitcomb R, Mclain R, Lockwood D. Impaired glucose tolerance is normalised by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997; 20: 188-193.
27. World Health Organisation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellittis. WHO/NCD/NCS/99.2. Geneva: World Health Organization, 1999.
28. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-284.
29. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycaemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-2064.
30. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-178.
31. Nilsson PM. Hypertension and diabetes mellitus. In Pickup JC, Williams G eds. Textbook of diabetes, 2nd edn, Vol. 2. Oxford: Blackwell Science, 1997; 56.1-56.19.
32. Salomaa VV, Strandberg TE, Vanhanen H, Naukkarinnen V, Sarna S, Meittinen TA. Glucose tolerance and blood pressure: long-term follow up in middle aged men. Br Med J 1991; 302: 493-496.
33. Nilsson P, Lind L, Andersson P-E, Hanni A, Berne C, Baron J et al. On the use of ambulatory blood pressure recordings and insulin sensitivity in support of the insulin-hypertension hypothesis. J Hypertens 1994; 12: 965-969.
34. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J et al. Preservation of pancreatic β-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.